Valuation: Guizhou Xinbang Pharmaceutical Co., Ltd.

Market Cap 5.61B 837M 744M 694M 633M 1.19B 80.48B 1.2B 8.4B 3.26B 41.14B 3.14B 3.08B 132B P/E 2024
91x
P/E 2025 50.8x
Enterprise Value 4.94B 736M 654M 611M 556M 1.05B 70.78B 1.06B 7.39B 2.86B 36.18B 2.76B 2.7B 116B EV / Sales 2024
1.39x
EV / Sales 2025 0.97x
Free-Float
53.97%
Yield 2024
1.32%
Yield 2025 2.8%
09-15 Guizhou Xinbang Pharmaceutical Co., Ltd. Approves Interim Cash Dividend (A Shares) for 2026, Payable on 29 September 2026 CI
08-28 Guizhou Xinbang Pharmaceutical Co., Ltd. Proposes Interim Cash Dividend for the Year 2026 CI
08-27 Guizhou Xinbang Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2026 CI
05-13 Guizhou Xinbang Pharmaceutical Co., Ltd. Approves Final Cash Dividend on A Shares for the Year 2025 Payable on 21 May 2026 CI
04-28 Guizhou Xinbang Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2026 CI
04-20 Guizhou Xinbang Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2025 CI
03-22 Guizhou Xinbang Pharmaceutical Co., Ltd.(XSEC:002390) dropped from FTSE All-World Index CI
25-10-28 Guizhou Xinbang Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2025 CI
25-09-18 Guizhou Xinbang Pharmaceutical Co., Ltd. Approves Implementation of Interim Profit Distribution Plan as Cash Dividend (A Shares) for 2025, Payable on 26 September 2025 CI
25-09-01 Guizhou Xinbang Pharmaceutical Co., Ltd. Proposes Interim Cash Dividend for 2025 CI
25-08-29 Guizhou Xinbang Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2025 CI
25-05-08 Guizhou Xinbang Pharmaceutical Co., Ltd. Approves Cash Dividend for the Year 2024 (A shares), Payable on 21 May 2025 CI
25-04-29 Guizhou Xinbang Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2025 CI
1 day+1.37%
1 week+1.72%
1 month-1.00%
3 months+8.03%
6 months-10.30%
Current year-8.07%
1 week 2.88
Extreme 2.88
2.98
1 month 2.88
Extreme 2.88
3.13
Current year 2.54
Extreme 2.54
3.49
1 year 2.54
Extreme 2.54
4.15
3 years 2.54
Extreme 2.54
5
5 years 2.54
Extreme 2.54
8
10 years 2.54
Extreme 2.54
12
Manager TitleAgeSince
Chief Executive Officer 58 2016-08-04
Director of Finance/CFO 53 2015-05-11
Investor Relations Contact 57 -
Director TitleAgeSince
Director/Board Member 58 2014-05-19
Chairman 33 2022-05-05
Director/Board Member 47 2023-05-11
Date Insider Type Main position Quantity % Market Cap. Importance
1/2/24 Buy

Chairman

3,106,200 0.1697%
10/18/22 Buy 392,300 0.0258%
10/12/22 Buy 213,600 0.0140%
Change 5-day change 1-year change 3-year change Capi.($)
+1.37%+1.72%-22.11%-38.33% 837M
-0.61%-3.43%+36.07%+117.61% 1,019B
-1.02%-5.60%+35.72%+64.82% 617B
+1.11%-0.58%+12.36%+78.27% 464B
+0.34%-3.01%+61.79%+41.79% 356B
-0.95%-4.05%+20.54%+40.33% 333B
-1.46%-2.89%+10.57%+26.54% 267B
-1.35%-5.43%-6.17%+8.82% 244B
-1.04%-2.79%+35.30%+54.42% 218B
-1.87%-4.10%+28.44%+97.54% 179B
Average -0.55%-3.05%+21.25%+49.18% 369.8B
Weighted average by Cap. -0.60%-3.32%+29.06%+71.13%

Financials

2024 2025
Net sales 6.03B 900M 799M 746M 680M 1.28B 86.49B 1.29B 9.03B 3.5B 44.21B 3.38B 3.3B 142B 5.62B 838M 745M 695M 634M 1.19B 80.57B 1.21B 8.41B 3.26B 41.19B 3.15B 3.08B 132B
Net income 101M 15.12M 13.43M 12.54M 11.43M 21.56M 1.45B 21.76M 152M 58.8M 743M 56.77M 55.54M 2.38B 120M 17.94M 15.94M 14.88M 13.56M 25.57M 1.72B 25.81M 180M 69.77M 882M 67.36M 65.89M 2.83B
Net Debt -228M -34M -30.21M -28.2M -25.7M -48.47M -3.27B -48.92M -341M -132M -1.67B -128M -125M -5.36B -677M -101M -89.72M -83.74M -76.32M -144M -9.71B -145M -1.01B -393M -4.96B -379M -371M -15.93B
Logo Guizhou Xinbang Pharmaceutical Co., Ltd.
Guizhou Xinbang Pharmaceutical Co Ltd is a China-based company primarily engaged in the provision of healthcare services. The Company operates three main businesses. Healthcare services business primarily provides oncology and general healthcare services. Pharmaceutical distribution business primarily comprises hospital-based drug and device distribution, a retail network, and supply chain solutions. Pharmaceutical manufacturing business primarily produces traditional Chinese medicines, herbal slices, and comprehensive health products. The Company primarily operates within domestic market.
Employees
4,702
Date Price Change Volume
26-09-30 CN¥2.960 +1.37% 20,037,063
26-09-29 CN¥2.920 -0.68% 21,672,470
26-09-28 CN¥2.940 +1.03% 20,636,745

Annual profits - Rate of surprise

  1. Stock Market
  2. Stocks
  3. 002390 Stock